HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours.
Whereas HER2 amplification is a well-known phenomenon in breast tumours, its frequency and clinical importance in ovarian cancer have not been established. The aim of the study was to compare the frequency of HER2 amplification in hereditary (BRCA-positive) and sporadic (BRCA-negative) ovarian tumours and to estimate the association of this gene alteration on clinical outcome in ovarian cancer patients. We analysed HER2 amplification in 53 ovarian tumours: 20 from mutation carriers (18 in BRCA1 and 2 in BRCA2 gene) and 33 from non-carriers. Fluorescence in situ hybridization for HER2 was performed on 'touch' slides from frozen tumour samples or formalin-fixed, paraffin-embedded tissue. Our results indicate that high amplification (HER2: centromere ratio>5) is an infrequent phenomenon in ovarian tumours (6/53 cases). It occurs in both hereditary (4/20) and sporadic (2/33) tumours and no difference in the frequency of HER2 amplification exists between these groups. There is no significant difference in the clinical outcome of patients with HER2 amplified and non-amplified tumours (p = 0.3). Our results suggest a different biological role of HER2 amplification in ovarian and breast cancer.
Brozek
Izabela
I
Department of Biology and Genetics, Medical University of Gdańsk. jlimon@amg.gda.pl.
Kardaś
Iwona
I
Ochman
Karolina
K
Debniak
Jarosław
J
Stukan
Maciej
M
Ratajska
Magdalena
M
Morzuch
Lucyna
L
Emerich
Janusz
J
Limon
Janusz
J